What one share of ARS Pharmaceuticals holds
This Annual Report also includes trademarks, trade names, and service marks that are the property of other organizations.
ARS Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.18 |
|---|---|
| Profit | −$2.17 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.98 |
| Cash and investments | $0.08 |
| Debt | $0.97 |
| Book value | $0.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$11.33 | $0.32 | −$11.04 | — | — |
| 2021 | — | −$0.70 | $0.00 | −$0.61 | — | −$1.03 |
| 2022 | — | −$0.87 | $0.01 | −$1.01 | — | — |
| 2023 | — | −$0.57 | $0.00 | −$0.62 | — | $2.39 |
| 2024 | $0.87 | $0.08 | $0.01 | $0.13 | — | $2.62 |
| 2025 | $0.85 | −$1.74 | $0.00 | −$1.74 | — | $1.15 |
Common questions about ARS Pharmaceuticals
How much does one share of ARS Pharmaceuticals earn?
Over the last 12 months, ARS Pharmaceuticals lost $2.17 for each share on $1.18 of sales.
Does ARS Pharmaceuticals pay a dividend?
ARS Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is ARS Pharmaceuticals’s book value per share?
ARS Pharmaceuticals’s book value is $0.13 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of ARS Pharmaceuticals have?
Each share of ARS Pharmaceuticals has $0.08 of cash and investments and $0.97 of debt, as of June 30, 2026.
What is ARS Pharmaceuticals’s free cash flow per share?
−$1.98 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has ARS Pharmaceuticals bought back shares?
ARS Pharmaceuticals’s share count rose about 3290% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.